Carotuximab
Carotuximab
Carotuximab (pronunciation: /ˌkærəˈtʌksɪmæb/) is a monoclonal antibody designed for the treatment of various types of cancer. It is an experimental drug that is currently under investigation in clinical trials.
Etymology
The term "Carotuximab" is derived from the Latin caro, meaning "flesh" or "meat", and the Greek toxikon, meaning "poison". The suffix "-mab" is an acronym for "monoclonal antibody".
Mechanism of Action
Carotuximab works by binding to a specific protein found on the surface of cancer cells, known as CD47. This binding inhibits the "don't eat me" signal that cancer cells send to avoid being destroyed by the body's immune system, allowing macrophages to recognize and destroy the cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- CD47: A protein found on the surface of many cells in the body, including cancer cells.
- Macrophage: A type of white blood cell that engulfs and digests cellular debris, foreign substances, microbes, and cancer cells.
Clinical Trials
As of now, Carotuximab is being studied in several clinical trials for its effectiveness in treating various types of cancer, including leukemia, lymphoma, and solid tumors.
Side Effects
Like all drugs, Carotuximab may cause side effects. The most common side effects reported in clinical trials include fatigue, fever, and nausea. More serious side effects can include allergic reactions and lung problems.
External links
- Medical encyclopedia article on Carotuximab
- Wikipedia's article - Carotuximab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski